Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim
Cancer Res Treat. 2024;56(3):721-742. Published online November 29, 2023
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim, Jung Hwan Ji, Joon Jeong, Kabsoo Shin, Jieun Lee, Hyung-Don Kim, Kyung Hae Jung, Joohyuk Sohn
Cancer Res Treat. 2023;55(4):1198-1209. Published online April 11, 2023
Purpose Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.
Citations
Citations to this article as recorded by
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data Alieke K. Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, Lennart J. Stoker, Jurjen S. Kingma, Mirjam K. Rommers, Emile M. Kuck, Paul D. van der Linden, Merel van Nuland Clinical Pharmacology & Therapeutics.2025;[Epub] CrossRef
Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo
Cancer Res Treat. 2023;55(1):123-135. Published online March 24, 2022
Purpose The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.
Citations
Citations to this article as recorded by
HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang Scientific Reports.2025;[Epub] CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang American Journal of Men's Health.2024;[Epub] CrossRef
Jieun Lee, Hyung Soon Park, Hye Sung Won, Ji Hyun Yang, Hee Yeon Lee, In Sook Woo, Kabsoo Shin, Ji Hyung Hong, Young Joon Yang, Sang Hoon Chun, Jae Ho Byun
Cancer Res Treat. 2021;53(2):409-423. Published online October 28, 2020
Purpose
Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.
Materials and Methods
Between April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed.
Results
Median age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).
Conclusion
To our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
Citations
Citations to this article as recorded by
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A. Gelmon Targeted Oncology.2024; 19(3): 303. CrossRef
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-l Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwas Breast Cancer.2024; 31(4): 621. CrossRef
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker Mehmet Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Tekin, Doğan Yazılıtaş Breast Cancer: Targets and Therapy.2024; Volume 16: 329. CrossRef
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang BMC Cancer.2024;[Epub] CrossRef
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet A. N. Sendur Oncology and Therapy.2024; 12(3): 395. CrossRef
Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) Yifan Chen, Yizhao Xie, Die Sang, Ning Xie, Xinhua Han, Yanxia Zhao, Juanjuan Li, Jian Yue, Peng Yuan, Biyun Wang Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang BMC Cancer.2023;[Epub] CrossRef
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program Carlo Palmieri, Alison Musson, Catherine Harper-Wynne, Duncan Wheatley, Gianfilippo Bertelli, Iain R. Macpherson, Mark Nathan, Ellie McDowall, Ajay Bhojwani, Mark Verrill, Joe Eva, Colm Doody, Ruhe Chowdhury British Journal of Cancer.2023; 129(5): 852. CrossRef
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço The Breast.2022; 62: 135. CrossRef
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy Current Oncology.2022; 29(3): 1761. CrossRef
Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study Lesang Shen, Jun Zhou, Yiding Chen, Jinhua Ding, Haiyan Wei, Jian Liu, Wenjie Xia, Bojian Xie, Xiaohong Xie, Xujun Li, Yuechu Dai, Guobing Zhang, Xia Qiu, Chao Li, Shanshan Sun, Wuzhen Chen, Dihe Gong, Hengyu Li, Jian Huang, Xia Jiang, Chao Ni Cancer Medicine.2022; 11(22): 4157. CrossRef
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia Weizhe Jian, Junsheng Xue, Qingyu Yao, Rong Chen, Ye Yao, Mopei Wang, Tianyan Zhou Cancer Chemotherapy and Pharmacology.2022; 90(6): 489. CrossRef
Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population Yusi Zhang, Wenlin Chen, Shuanglong Chen, Qingmo Yang, Zhong Ouyang Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law Clinical Therapeutics.2022; 44(12): 1588. CrossRef
Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval Scientific Reports.2021;[Epub] CrossRef
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Ji-Yeon Kim, Jung Min Oh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im Frontiers in Oncology.2021;[Epub] CrossRef
Purpose
Tumor-infiltrating lymphocyte (TIL), programmed death-ligand 1 (PD-L1) expression and neutrophil-to-lymphocyte ratio (NLR) is associated to immunogenicity and prognosis of breast cancer. We analyzed baseline NLR, changes of NLR, TIL, and PD-L1 during neoadjuvant chemotherapy (NAC) and their clinical implication in triple-negative breast cancer (TNBC).
Materials and Methods
Between January 2008 to December 2015, 358 TNBC patients were analyzed. Baseline NLR, 50 paired NLR (initial diagnosis, after completion of NAC) and 34 paired tissues (initial diagnosis, surgical specimen after completion of NAC) were collected. Changes of TIL, CD4, CD8, forkhead box P3 (FOXP3), and PD-L1 expression were assessed with immunohistochemical stain.
Results
Low NLR (≤ 3.16) was associated to superior survival (overall survival: 41.83 months vs. 36.5 months, p=0.002; disease-free survival [DFS]: 37.85 months vs. 32.14 months, p=0.032). Modest NLR change after NAC (–30% < NLR change < 100%) showed prolonged DFS (38.37 months vs. 22.37 months, p=0.015). During NAC, negative or negative conversion of tumor PD-L1 expression was associated to poor DFS (34.77 months vs. 16.03 months, p=0.037), and same or increased TIL showed trends for superior DFS, but without statistical significance. Positive tumor PD-L1 expression (H-score ≥ 5) in baseline or post- NAC tissue was associated to superior DFS (57.6 months vs. 12.5 months, p=0.001 and 53.3 months vs. 18.9 months, p=0.040). Positive stromal PD-L1 expression in baseline was also associated to superior DFS (50.2 months vs. 20.4 months, p=0.002).
Conclusion
In locally advanced TNBC, baseline NLR, changes of NLR during NAC was associated to survival. Baseline PD-L1 expression and changes of PD-L1 expression in tumor tissue during NAC also showed association to prognosis.
Citations
Citations to this article as recorded by
Neutrophil–lymphocyte ratio reflects tumour‐infiltrating lymphocytes and tumour‐associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy Joshua J X Li, Shelly Y B Ni, Julia Y S Tsang, Wai Yin Chan, Ray K W Hung, Joshua W H Lui, Sally W Y Ng, Leong Kwong Shum, Ying Fei Tang, Gary M Tse Histopathology.2024; 84(5): 810. CrossRef
Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer Xingyu Li, Yanyan Zhang, Cheng Zhu, Wentao Xu, Xiaolei Hu, Domingo Antonio Sánchez Martínez, José Luis Alonso Romero, Ming Yan, Ying Dai, Hua Wang BMC Women's Health.2024;[Epub] CrossRef
Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, Gaurisha Alias Resha Ramnath Naik, Sarika Yadav, Shreya Srivastava, Amrita Arup Roy, Sudheer Moorkoth, Srinivas Mutalik, Namdev Dhas Journal of Drug Delivery Science and Technology.2024; 93: 105401. CrossRef
Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis Guangfa Xia, Ziran Zhang, Qin Jiang, Huan Wang, Jie Wang Medicine.2024; 103(6): e36810. CrossRef
The prognostic value of preoperative neoindices consisting of lymphocytes, neutrophils and albumin (LANR) in operable breast cancer: a retrospective study Yuan Wang, Jiaru Zhuang, Shan Wang, Yibo Wu, Ling Chen PeerJ.2024; 12: e17382. CrossRef
A review concerning the breast cancer-related tumour microenvironment Oscar Hernán Rodríguez-Bejarano, Carlos Parra-López, Manuel Alfonso Patarroyo Critical Reviews in Oncology/Hematology.2024; 199: 104389. CrossRef
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef
Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis Gavin P Dowling, Gordon R Daly, Aisling Hegarty, Sandra Hembrecht, Aisling Bracken, Sinead Toomey, Bryan T Hennessy, Arnold D K Hill British Journal of Surgery.2024;[Epub] CrossRef
Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer Elena Provenzano, Abeer M Shaaban Histopathology.2023; 82(1): 170. CrossRef
Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar, Sunil Kumar Dubey Pharmaceutics.2023; 15(1): 246. CrossRef
The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I–III triple-negative breast cancer Guang-Yi Sun, Jing Zhang, Bing-Zhi Wang, Hao Jing, Hui Fang, Yu Tang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Bo Chen, Ning-Ning Lu, Ning Li, Ye-Xiong Li, Jian-Ming Ying, Shu-Lian Wang British Journal of Cancer.2023; 128(11): 2044. CrossRef
Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis Manuela Llano-León, Laura Camila Martínez-Enriquez, Oscar Mauricio Rodríguez-Bohórquez, Esteban Alejandro Velandia-Vargas, Nicolás Lalinde-Ruíz, María Alejandra Villota-Álava, Ivon Johanna Rodríguez-Rodríguez, María del Pilar Montilla-Velásquez, Carlos Al PLOS ONE.2023; 18(4): e0277714. CrossRef
Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: A retrospective observational cohort study Sarosh Khan Jadoon, Rufina Soomro, Muhammad Nadeem Ahsan, Raja Muhammad Ijaz Khan, Sadia Iqbal, Farah Yasmin, Hala Najeeb, Nida Saleem, Namiya Cho, Resham, Taha Gul Shaikh, Syeda Fatima Saba Hasan, Muhammad Zain Khalid, Sarosh Alvi, Ahsan Mujtaba Rizvi, Medicine.2023; 102(20): e33811. CrossRef
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients Esmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Elisa García-Garre, Francisco Ayala de la Peña, Elena García-Martínez Frontiers in Oncology.2023;[Epub] CrossRef
Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer Meng Zhao, Hui Xing, Jiankun He, Xinran Wang, Yueping Liu Pathology - Research and Practice.2023; 248: 154687. CrossRef
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity Andrea Nicolini, Giuseppe Rossi, Paola Ferrari, Angelo Carpi Seminars in Cancer Biology.2022; 79: 68. CrossRef
The advanced lung cancer inflammation index is a novel independent prognosticator in colorectal cancer patients after curative resection Taichi Horino, Ryuma Tokunaga, Yuji Miyamoto, Yukiharu Hiyoshi, Takahiko Akiyama, Nobuya Daitoku, Yuki Sakamoto, Naoya Yoshida, Hideo Baba Annals of Gastroenterological Surgery.2022; 6(1): 83. CrossRef
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer Yiqi Fan, Shuai He Cancer Management and Research.2022; Volume 14: 1. CrossRef
Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer Meng Li, Junnan Xu, Cui Jiang, Jingyan Zhang, Tao Sun Frontiers in Oncology.2022;[Epub] CrossRef
PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy Ahmad Alhesa, Heyam Awad, Sarah Bloukh, Mahmoud Al-Balas, Mohammed El-Sadoni, Duaa Qattan, Bilal Azab, Tareq Saleh International Journal of Immunopathology and Pharmacology.2022;[Epub] CrossRef
Circulating proteins as predictive and prognostic biomarkers in breast cancer Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando Clinical Proteomics.2022;[Epub] CrossRef
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy Silvia D’Amico, Patrizia Tempora, Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, Franco Locatelli, Doriana Fruci Frontiers in Immunology.2022;[Epub] CrossRef
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Hamdy A. Azim, Kyrillus S. Shohdy, Hagar Elghazawy, Monica M. Salib, Doaa Almeldin, Loay Kassem Biomarkers.2022; 27(8): 764. CrossRef
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation Mariana Segovia-Mendoza, Susana Romero-Garcia, Cristina Lemini, Heriberto Prado-Garcia, francesca bianchi Journal of Immunology Research.2021; 2021: 1. CrossRef
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survival Sandeep K. Singhal, Jung S. Byun, Samson Park, Tingfen Yan, Ryan Yancey, Ambar Caban, Sara Gil Hernandez, Stephen M. Hewitt, Heike Boisvert, Stephanie Hennek, Mark Bobrow, Md Shakir Uddin Ahmed, Jason White, Clayton Yates, Andrew Aukerman, Rami Vanguri, R Communications Biology.2021;[Epub] CrossRef
Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Jian Pang, Haiyan Zhou, Xue Dong, Shouman Wang, Zhi Xiao Clinical Breast Cancer.2021; 21(6): e681. CrossRef
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Michael Hauptmann, Katarzyna Jozwiak, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claud Journal for ImmunoTherapy of Cancer.2021; 9(5): e002198. CrossRef
Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis M G Davey, É J Ryan, M S Davey, A J Lowery, N Miller, M J Kerin British Journal of Surgery.2021; 108(6): 622. CrossRef
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer Hugo Veyssière, Sejdi Lusho, Ioana Molnar, Myriam Kossai, Maureen Bernadach, Catherine Abrial, Yannick Bidet, Nina Radosevic-Robin, Xavier Durando Frontiers in Oncology.2021;[Epub] CrossRef
Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines Karen Bräutigam, Elodie Kabore-Wolff, Ahmad Fawzi Hussain, Stephan Polack, Achim Rody, Lars Hanker, Frank Köster Journal of Cancer Research and Clinical Oncology.2021; 147(10): 2923. CrossRef
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting Antonino Grassadonia, Vincenzo Graziano, Laura Iezzi, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Giuseppe Cicero, Eriseld Krasniqi, Marco Mazzotta, Daniele Marinelli, Antonella Amodio, Clara Natoli, Nicola Tinari Cells.2021; 10(7): 1685. CrossRef
Time-Sequencing of the Neutrophil-to-Lymphocyte Ratio to Predict Prognosis of Triple-Negative Breast Cancer Joo-Heung Kim, Nak-Hoon Son, Jun-Sang Lee, Ji-Eun Mun, Jee-Ye Kim, Hyung-Seok Park, Seho Park, Seung-Il Kim, Byeong-Woo Park Cancers.2021; 13(14): 3472. CrossRef
Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients Sejdi Lusho, Xavier Durando, Marie-Ange Mouret-Reynier, Myriam Kossai, Nathalie Lacrampe, Ioana Molnar, Frederique Penault-Llorca, Nina Radosevic-Robin, Catherine Abrial Frontiers in Oncology.2021;[Epub] CrossRef
Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis Qiong Zhou, Jie Dong, Qingqing Sun, Nannan Lu, Yueyin Pan, Xinghua Han BMJ Open.2021; 11(9): e047957. CrossRef
Neutrophil to Lymphocyte Ratio after Treatment Completion as a Potential Predictor of Survival in Patients with Triple-Negative Breast Cancer Kwang-Min Kim, Hyang Suk Choi, Hany Noh, In-Jeong Cho, Seung Taek Lim, Jong-In Lee, Airi Han Journal of Breast Cancer.2021; 24(5): 443. CrossRef
Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures Fei Ji, Jiao-Mei Yuan, Hong-Fei Gao, Ai-Qi Xu, Zheng Yang, Ci-Qiu Yang, Liu-Lu Zhang, Mei Yang, Jie-Qing Li, Teng Zhu, Min-Yi Cheng, Si-Yan Wu, Kun Wang Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review Iléana Corbeau, William Jacot, Séverine Guiu Cancers.2020; 12(4): 958. CrossRef
A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment Wei Zhang, Yimin Shen, Huanhuan Huang, Sheng Pan, Jingxin Jiang, Wuzhen Chen, Ting Zhang, Chao Zhang, Chao Ni Frontiers in Immunology.2020;[Epub] CrossRef
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies Gagan K. Gupta, Amber L. Collier, Dasom Lee, Richard A. Hoefer, Vasilena Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston, Billur Samli, Rick J. Jansen, Emanuel F. Petricoin, Matthew P. Goetz, Ha Cancers.2020; 12(9): 2392. CrossRef
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study Parisa Lotfinejad, Mohammad Asghari Jafarabadi, Mahdi Abdoli Shadbad, Tohid Kazemi, Fariba Pashazadeh, Siamak Sandoghchian Shotorbani, Farhad Jadidi Niaragh, Amir Baghbanzadeh, Nafiseh Vahed, Nicola Silvestris, Behzad Baradaran Diagnostics.2020; 10(9): 704. CrossRef
Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers A. Gouri, B. Benarba, A. Dekaken, H. Aoures, S. Benharkat Current Drug Targets.2020; 21(10): 1008. CrossRef
Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals Wanying Guo, Xin Lu, Qipeng Liu, Ting Zhang, Peng Li, Weiqiang Qiao, Miao Deng Cancer Medicine.2019; 8(9): 4135. CrossRef
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis Wenfa Huang, Ran Ran, Bin Shao, Huiping Li Breast Cancer Research and Treatment.2019; 178(1): 17. CrossRef
Comparison of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Bladder Cancer Patients Undergoing Radical Cystectomy Ruiliang Wang, Yang Yan, Shenghua Liu, Xudong Yao BioMed Research International.2019; 2019: 1. CrossRef
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli, N. Tinari, G. Ciliberto, M. Barba, P. Vici Journal of Hematology & Oncology.2019;[Epub] CrossRef
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos Sotiriou, Jonas Bergh, Antonios Valachis, Theodoros Foukakis Clinical Cancer Research.2019; 25(18): 5717. CrossRef
Purpose Gemcitabine-cisplatin combination chemotherapy has been regarded as standard regimen for advanced or metastatic biliary tract cancer (BTC), based on the ABC-02 trial. To date, however, no studies have compared the efficacies of gemcitabine-platinum and fluoropyrimidine- platinum combination chemotherapy, even though fluoropyrimidine has been widely used as a backbone agent for gastrointestinal cancer. This study compared the efficacy and toxicities of gemcitabine-cisplatin (GP) and capecitabine-cisplatin (XP) combination chemotherapy for treatment of advanced BTC. Materials and Methods We examined 49 patients treated with GP and 44 patients treated with XP from October 2009 to July 2012. All patients had unresectable BTC. The GP regimen comprised gemcitabine (1,000 mg/m2, intravenously [IV], days 1 and 8) and cisplatin (75 mg/m2, IV, day 1). The XP regimen comprised capecitabine (1,250 mg/m2 twice a day, peroral, days 1-14) and cisplatin (60 mg/m2, IV, day 1, every three weeks). We analyzed the response rate (RR), time to progression (TTP), overall survival (OS), and toxicity. Results The RRs were 27.3% and 6.1% in the XP and GP arms, respectively. XP resulted in longer TTP (5.2 months vs. 3.6 months, p=0.016), but OS was not statistically different (10.7 months vs. 8.6 months, p=0.365). Both regimens resulted in grade 3-4 hematologic toxicities, but febrile neutropenia was not noted. Grade 3-4 asthenia, stomatitis, and hand-foot syndrome occurred more frequently in the XP arm. Conclusion XP resulted in a superior TTP and RR compared to GP for treatment of advanced BTC, with comparable toxicity. Conduct of prospective large, randomized trials to evaluate the possibility of XP as another standard therapy is warranted.
Citations
Citations to this article as recorded by
Pristine B
40
fullerene as a potential gemcitabine drug carrier for anti-lung cancer properties: a DFT and QTAIM study
Abisha Nancy Sukumar, Parimala Devi Duraisamy, Prince Makarios Paul. S, Praveena Gopalan, Abiram Angamuthu Journal of Biomolecular Structure and Dynamics.2024; : 1. CrossRef
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin Current Oncology.2023; 30(8): 7132. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal Targeted Oncology.2023; 18(6): 837. CrossRef
Chemotherapy for Biliary Tract Cancer in 2021 Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Masato Ozaka, Naoki Sasahira Journal of Clinical Medicine.2021; 10(14): 3108. CrossRef
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis Ting Zheng, Jianjiang Jin, Li Zhou, Yuefeng Zhang Oncology Research and Treatment.2020; 43(9): 460. CrossRef
The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis Yan Li, Yaoyao Zhou, Yonglan Hong, Meizhi He, Shuyi Wei, Chen Yang, Dayong Zheng, Feiye Liu Frontiers in Oncology.2019;[Epub] CrossRef
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas Omar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, Weilin Wang British Journal of Cancer.2018; 119(3): 291. CrossRef
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang Cancer Research and Treatment.2017; 49(3): 807. CrossRef
Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer Jang Han Jung, Hee Seung Lee, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park Chemotherapy.2017; 62(6): 361. CrossRef
The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen Oncotarget.2017; 8(59): 100657. CrossRef